batirtze-areitio Batirtze Areitio Batirtze has over 5 years of experience in the biopharma and biotech industries. She joined ApexOnco in 2025 after working as an analyst at OncologyPipeline. She is a graduate of the University of Navarra, where she earned a degree in biochemistry. Abecma’s first-line hopes dashed 25 September 2024 Merck’s favezelimab is latest Lag3 to falter 25 September 2024 Context could herald what’s next for Nectin-4 24 September 2024 The EU door to China-based approvals is open 23 September 2024 Akeso’s CD47 heads for phase 3 23 September 2024 Dato sees double survival trouble 23 September 2024 Achilles follows Instil’s lead 19 September 2024 Merck’s patritumab-dxd case strengthens 18 September 2024 Load More